Xanthine oxidase-IN-23

Overview

Xanthine oxidase-IN-23 (Compound BPF) is an orally active, reversible, mixed-type Xanthine oxidase inhibitor with an IC 50 of 3.33 μM. Xanthine oxidase-IN-23 directly binds to XOD in a reversible mixed-type manner to inhibit its catalytic activity. Xanthine oxidase-IN-23 upregulates ABCG2 and downregulates GLUT9 to promote renal urate excretion. Xanthine oxidase-IN-23 reduces serum urate levels and improves renal function in hyperuricemic mice. Xanthine oxidase-IN-23 can be used in the research of hyperuricemia.

Application

Products | Products > Disease Areas > Purine Metabolism | Products > Disease Areas > Hyperuricemia | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > Free Radical Scavengers | Products > Signaling Pathways > Xanthine Oxidase | Products > Signaling Pathways > BCRP | Products > Signaling Pathways > GLUT

Product Information

• Catalog No.: HY-182000
• CAS No.: 3055112-52-9
• Molecular Formula: C17H12Br2O5
• Molecular Weight: 456.08
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source